导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.59% | 1592/4773 |
| 近一周 | -1.89% | 3083/5465 |
| 近一月 | -3.13% | 2200/5421 |
| 近一季 | -5.30% | 2031/5231 |
| 近半年 | 1.91% | 1113/4920 |
| 近一年 | 7.88% | 1408/4394 |
| 近两年 | 54.94% | 1367/2954 |
| 近三年 | 34.03% | 943/2253 |
| 成立以来 | 71.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.57% 2825/4961 |
13.86% 1928/5312 |
- - |
- - |
| 2025 | 24.02% 1821/4813 |
0.07% 1987/3635 |
2.05% 1924/4076 |
20.20% 2014/4524 |
1.04% 1578/4813 |
| 2024 | 13.12% 1173/3463 |
4.56% 447/2808 |
-1.76% 1104/3014 |
13.39% 2177/3129 |
-2.88% 2198/3463 |
| 2023 | -17.95% 1770/2656 |
4.84% 862/2280 |
-5.25% 1408/2385 |
-10.51% 2004/2515 |
-7.70% 2191/2655 |
| 2022 | -21.49% 1037/2207 |
-17.15% 1184/1919 |
11.05% 252/2016 |
-13.91% 992/2113 |
-0.88% 1656/2208 |
| 2021 | -1.14% 784/1822 |
-1.08% 428/1255 |
7.69% 672/1330 |
-10.52% 1226/1466 |
3.72% 398/1822 |
| 2020 | 44.90% 223/1250 |
-5.38% 413/1028 |
21.17% 245/1067 |
12.50% 383/1164 |
12.34% 477/1184 |
| 2019 | 42.82% 203/1092 |
23.45% 555/739 |
-1.00% 284/788 |
5.51% 147/850 |
10.76% 99/918 |
| 2018 | -13.50% 88/834 |
- - |
4.38% 9/631 |
-0.52% 189/660 |
-10.84% 232/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇安沪深300指数增强A VS. 长安沪深300非周期A(740101) |